T. V. Rakitina, A. A. Zeifman, I. Yu. Titov, I. Svitanko, A. V. Lipkin, V. S. Stroylov, O. V. Stroganov, F. N. Novikov, G. G. Chilov, “Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer”, Mendeleev Commun., 2012, Volume 22, Issue 6,Pages <nobr>287–289</nobr>

RUS ENG

JOURNALS // Mendeleev Communications // Archive

Mendeleev Commun., 2012 Volume 22, Issue 6, Pages 287–289 (Mi mendc2822)

This article is cited in 2 papers

Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer

T. V. Rakitina^ab, A. A. Zeifman^cd, I. Yu. Titov^cd, I. Svitanko^d, A. V. Lipkin^be, V. S. Stroylov^cd, O. V. Stroganov^cd, F. N. Novikov^cd, G. G. Chilov^cd

^a M.M. Shemyakin–Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
^b National Research Centre 'Kurchatov Institute', Moscow, Russian Federation
^c MolTech Ltd, Moscow, Russian Federation
^d N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
^e A.N. Bach Institute of Biochemistry, Russian Academy of Sciences, Moscow, Russian Federation

Abstract: Novel rationally-designed Syk-kinase inhibitor MT-SYK-03 demonstrated equal potency with R406 (active metabolite of Fostamatinib, a phase III clinical trial candidate) in cellular models of autoimmunity and cancer with EC50 values in sub-micromolar range, while MT-SYK-322 was less active.

Language: English

DOI: 10.1016/j.mencom.2012.11.001

Fulltext: PDF file (348 kB)
Cited by

	*Supplementary materials:*
		Supplementary_data_1.pdf	165.6 Kb

© Steklov Math. Inst. of RAS, 2025